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Abstract
To facilitate viral infection and spread, HIV-1 Nef disrupts the surface expression of the viral receptor (CD4) and molecules
capable of presenting HIV antigens to the immune system (MHC-I). To accomplish this, Nef binds to the cytoplasmic tails of
both molecules and then, by mechanisms that are not well understood, disrupts the trafficking of each molecule in different
ways. Specifically, Nef promotes CD4 internalization after it has been transported to the cell surface, whereas Nef uses the
clathrin adaptor, AP-1, to disrupt normal transport of MHC-I from the TGN to the cell surface. Despite these differences in
initial intracellular trafficking, we demonstrate that MHC-I and CD4 are ultimately found in the same Rab7
+ vesicles and are
both targeted for degradation via the activity of the Nef-interacting protein, b-COP. Moreover, we demonstrate that Nef
contains two separable b-COP binding sites. One site, an arginine (RXR) motif in the N-terminal a helical domain of Nef, is
necessary for maximal MHC-I degradation. The second site, composed of a di-acidic motif located in the C-terminal loop
domain of Nef, is needed for efficient CD4 degradation. The requirement for redundant motifs with distinct roles supports a
model in which Nef exists in multiple conformational states that allow access to different motifs, depending upon which
cellular target is bound by Nef.
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Introduction
The HIV-1 accessory protein, Nef, affects the biology of the
infected cell in several ways to achieve conditions optimal for viral
replication and spread. Nef alters the intracellular trafficking of
important immune molecules, such as class I and II major
histocompatibility complex proteins (MHC-I and MHC-II), CD4,
CD28, and DC-SIGN [1–5]. Nef-dependent reduction of surface
MHC-I protects HIV-infected primary T cells from recognition
and killing by HIV-specific cytotoxic T lymphocytes (CTLs) in vitro
[6]. Moreover, disruption of MHC-I expression by HIV-1 and
SIV Nef provides a selective advantage under immune pressure in
vivo [7–10]. CD4 downregulation by Nef is also essential for
efficient viral spread. The rapid removal of CD4 prevents viral
superinfection [11], and enables optimal viral particle production
by eliminating detrimental CD4/HIV envelope interactions in the
infected cell [12,13].
Mutagenesis of protein-protein interaction domains has revealed
that Nef uses genetically separable mechanisms to affect MHC-I and
CD4 transport. Specifically, disruption of MHC-I surface expression
requires an N-terminal a helix, a polyproline repeat, and an acidic
domaininNef[14,15],whileCD4downregulationrequiresanintact
dileucinemotif,twodiacidicmotifs,andahydrophobicpocketinNef
[15–18]. Amino acids necessary for the myristoylation [19,20] and
oligomerization [21] of Nef are required for the disruption of both
MHC-I and CD4 surface expression.
Nef has the capacity to affect MHC-I transport at multiple
subcellular locations; Nef blocks the export of newly-synthesized
MHC-I from the secretory pathway and Nef expression results in a
small increase in the rate of MHC-I internalization [22]. To
accomplish this, Nef directly binds to the cytoplasmic tail of MHC-
I early in the secretory pathway [23–26]. The Nef-MHC-I
complex then actively recruits the clathrin adaptor protein
complex AP-1, which targets MHC-I from the TGN to the
endo-lysosomal network where it is ultimately degraded [25].
Recruitment of AP-1 primarily requires a methionine at position
20 in the N-terminal a helical domain of Nef and a tyrosine
residue in the cytoplasmic tail of MHC-I. Additionally, the acidic
and polyproline domains of Nef have recently been shown to
stabilize this interaction [27,28]. The normal function of AP-1 is to
target proteins into the endosomal pathway and then recycle them
back to the TGN. Thus, the AP-1 interaction with the Nef/MHC-
I complex explains the targeting of MHC-I containing vesicles to
the endosomal pathway and to the TGN. However, it does not
explain accelerated degradation of MHC-I, hence other cellular
factors may be involved [25].
The mechanism of Nef-induced CD4 internalization and
degradation has been derived, in part, from correlating Nef
PLoS Pathogens | www.plospathogens.org 1 August 2008 | Volume 4 | Issue 8 | e1000131function with the requirement for domains in the C-terminal
flexible loop region of Nef that bind to cellular factors. The Nef
dileucine motif (ExxxLL165) is needed for CD4 internalization and it
binds to adaptor protein complexes AP-1, AP-2, and AP-3 [16,29–
36]. In addition, a diacidic motif, which is also required, enhances
theinteractionofNefwithAP-2[37].Thereisseparateevidencethat
this diacidic motif may recruit the H subunit of the vacuolar ATPase
(V1H) [38] to promote AP-2 recruitment [39]. Because the normal
role of AP-2 is to link cargo to clathrin and promote internalization,
it makes sense that this molecule would be necessary and indeed, the
involvement of AP-2 has now been confirmed using RNAi
knockdown in a number of cell systems [40–42].
After CD4 is internalized, it is targeted to lysosomes for
degradation. There is evidence that this step requires b-COP [18],
a component of COP-1 coats implicated in endosomal trafficking
as well as transport through the early secretory pathway [43–45].
Specifically, there are defects in the Nef-dependent transport of
CD4 into acidified vesicles at the non-permissive temperature in
cells harboring a temperature sensitive e-COP mutant [18]. Nef
directly interacts with b-COP [46], and a second diacidic motif in
the C-terminal loop domain of Nef has been demonstrated to
mediate this interaction [18,47], although, this result has not been
reproducible by another group [48].
To more clearly understand the mechanism of altered MHC-I
and CD4 trafficking observed in Nef-expressing cells, we directly
compared these two processes in T cells that expressed Nef. We
confirmed that Nef primarily affected MHC-I and CD4 at
different subcellular locations and we demonstrated that the
cytoplasmic tails of the respective molecules dictated which
pathway was utilized. Despite the differences in initial trafficking,
we found that HLA-A2 and CD4 co-localized in a discrete subset
of vesicular structures. Upon further inspection, we determined
that these structures also contained markers of late endosomes
(Rab7) and to a lesser extent, the lysosomal marker, LAMP-1.
Electron microscopy (EM) revealed that CD4 and HLA-A2 were
found within MVBs of Nef-expressing T cells. HLA-A2 (but not
CD4) was also found in tubulovesicular structures adjacent to the
Golgi. In Nef expressing cells, reduction of b-COP expression
reduced the targeting of HLA-A2 from the TGN to LAMP-1
+
compartments and stabilized CD4 expression within endosomal
compartments. Finally, we identified two separate domains within
Nef that were necessary for these activities and for b-COP binding.
These data support a model in which both MHC-I and CD4 are
ultimately targeted to the lysosomes in Nef expressing cells by a
final common pathway.
Results
The cytoplasmic tail dictates the pathway utilized by Nef
to eliminate MHC-I and CD4 surface expression
ItisknownthatNefbindstothecytoplasmictailsofbothCD4and
MHC–I,butthatitaffectsthemdifferently.Tobetterunderstandthe
similarities and differences governing these two pathways, we
examined the trafficking of CD4, HLA-A2 and a chimeric molecule
in which the wild type HLA-A2 cytoplasmic tail was substituted with
the CD4 cytoplasmic tail (HA-A2/CD4). A flow cytometric analysis
of steady state surface expression revealed that Nef dramatically
reduced steady state surface expression of all three molecules
(Figure 1A). Consistent with prior studies, we found that CD4 was
rapidly internalized from the cell surface in Nef expressing T cells,
whereas wild type HLA-A2 was not (Figure 1B). Substitution of the
CD4tailforthe HLA-A2cytoplasmictailwas sufficienttoconferthis
phenotype (Figure 1C). Conversely, prior studies have shown that
Nef disrupts cell surface expression of MHC-I by blocking the
transport of newly synthesized MHC-I from the TGN to the cell
surface [22,23]. As shown in Figure 1D, Nef inhibited HLA-A2
forward transport by approximately 75%, whereas CD4 was
unaffected at Nef levels that had a clear effect on HLA-A2 transport.
Slight effects on CD4 could be observed at higher Nef levels
(Figure 1D, lane 8). The substitution of the HLA-A2 cytoplasmic tail
with the CD4 tail reduced the ability of Nef to disrupt forward
trafficking (Figure 1E). Thus, sequences in the cytoplasmic tails of
CD4 and HLA-A2 determine how Nef disrupts their trafficking.
CD4 and a subset of HLA-A2 proteins are found in late
endosomes and lysosomes of Nef-expressing T cells
To better understand the similarities and differences between
MHC-I and CD4 trafficking in Nef-expressing cells, we compared
the steady-state distribution of these molecules in T cells using
confocal microscopy (Figure 2A). We found that Nef expression
caused the bulk of MHC-I to cluster in the perinuclear region
where, in agreement with many other studies [14,30,49], it co-
localized with markers of the TGN (data not shown). Interestingly,
we also identified a subset of HLA-A2 that co-localized with CD4
in vesicular structures (Figure 2A; arrows show example vesicles).
To further identify these structures, we simultaneously stained for
HLA-A2, CD4, and organelle markers using 3-color confocal
microscopy (summarized in Table S1). Our results indicated that
CD4 was mainly found in discrete vesicular structures, which also
contained HLA-A2 (91.9% of the CD4
+ vesicles co-localized with
HLA-A2, Table S1) and markers of late endosomes and lysosomes.
Overall, the best marker for structures containing both HLA-A2
and CD4 was Rab7 (94%, of CD4+ vesicles co-localized with Rab
7, Table S1 and Figure 2A, arrowheads mark example vesicles).
CD4 and HLA-A2 were also found to co-localize with markers of
lysosomes, such as LAMP-1. However, the vesicles with the most
intense LAMP-1 staining did not contain either HLA-A2 or CD4,
possibly because of degradation. Consistent with this, the co-
localization of HLA-A2 and CD4 was dramatically increased
when the cells were treated with bafilomycin, which inhibits
degradation in acidic compartments (Figure S1). Thus, the normal
steady-state co-localization of HLA-A2 and CD4 in Nef expressing
Author Summary
HIV is unique among viral pathogens in its capacity to cause
chronic and progressive disease in almost all infected
people. To accomplish this, HIV must evade the host
immuneresponse,especiallycytotoxicTlymphocytes(CTLs),
which normally function to lyse virally infected cells. HIV
encodes a factor, Nef, which protects HIV infected cells from
lysis by anti-HIV CTLs. To prevent CTL lysis, Nef interferes
with the expression of host MHC-I, which is needed for CTL
recognition of infected targets. A clear understanding of
how Nef works has been hampered by its many complex
functions. In addition to MHC-I, Nef protein disrupts the
expression of multiple other cellular targets using different
mechanisms and it is unclear how one protein can
accomplish all these tasks. Here, we provide evidence that
Nef actsasa highlyflexibleadaptor protein thatis capable of
utilizing different protein binding domains depending on
which cellular target it is bound to. For example, we present
evidencethatNef bindingtoMHC-I createsnovel motifs that
result in the recruitment of AP-1 and subsequently b-COP.
This series of events results in the mis-localization of MHC-I
from the cell surface to cellular degradative compartments,
where MHC-I is destroyed.
Nef-Induced MHC-I and CD4 Degradation
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this compartment.
Colocalization of HLA-A2 and CD4 in MVBs
To further discern these structures, we also examined them
using electron microscopy (EM). In agreement with the confocal
data, our EM analysis revealed that compared with control cells in
which both HLA-A2 and CD4 were found on the cell surface
(Figure 2B, panel 1), in Nef-expressing T cells, the majority of
CD4 was found in MVBs, co-localizing with HLA-A2 (Figure 2B,
panel 2). In addition, we also noted substantial HLA-A2, but not
CD4, accumulating in tubulovesicular structures adjacent to Golgi
stacks (Figure 2B, panel 3). In separate experiments these
structures were also found to contain AP-1 (Figure 2C). Based
on these studies, it appears that the majority of HLA-A2 resides in
tubulovesicular structures in the region of the TGN with AP-1,
whereas at any given time, a small subset can be found in the
endosomal compartment with CD4.
Required cellular co-factors
To further elucidate the similarities and differences between
these pathways, we examined the role of known Nef-interacting
proteins implicated in intracellular trafficking. AP-1 is a hetero-
tetrameric adaptor protein involved in protein sorting from the
TGN and it has been previously demonstrated to interact with
MHC-I molecules in Nef expressing HIV-infected primary T cells
and to direct MHC-I into the endolysosomal pathway [25]. Nef is
also known to interact with b-COP [46], a component of COP-1
vesicles also involved in endosomal trafficking [43–45]. Indeed,
expression of wild type COP 1 components is needed for targeting
CD4 into acidic vesicles in Nef-expressing cells [18].
To compare and contrastthe requirement for thesefactors inNef-
dependent CD4 and HLA-A2 trafficking, we knocked down their
expression using lentiviral vectors expressing short hairpin RNAs
(shRNAs) [50]. All of these studies were performed in T cells and
new cell lines were generated for each experiment to eliminate the
possibility that long term growth in culture would select for cells that
had compensatedforthe defect.Using thissystem, we obtainedgood
knock downof them1 subunitof AP-1and b-COP (Figure 3A–C). (A
small apparent effect of shb-COP on m1 levels observable in
Figure 3A was not significant when adjusted for protein loading in
the experiment shown here or in replicate experiments [Figure 3B].
Wealso did not observe anyeffectofanothersiRNA directedagainst
a different target site in b-COP on m1 expression [Figure S2].)
Figure 1. The cytoplasmic tail domain of MHC-I and CD4 determines the mechanism by which Nef affects trafficking. (A) Reduction of
surface expression of HLA-A2, CD4 and A2/CD4 as measured by flow cytometry. CEM HA-HLA-A2 and CEM HA-A2/CD4 cells were transduced with a
control adenovirus (nef
2) or adeno-Nef (nef
+) and stained for surface HLA-A2 and CD4. The histograms shaded gray represent cells treated with
control adenovirus, and the solid black line indicates cells treated with adeno-Nef. (B-C) Measurements of surface stability. CEM HA-HLA-A2 and HA-
A2/CD4 cells were treated with adenovirus as in part A and the internalization of endogenous CD4 (B) or A2/CD4 (C) was compared to the
internalization of HLA-A2. The filled squares represent control (nef2) cells, and the open squares represent adeno-Nef (nef
+) cells. Quantitation of part
B was compiled from four independent experiments performed in duplicate. Part C is representative of two experiments performed in triplicate. (D–E)
HLA-A2 is inefficiently transported to the cell surface in T cells expressing Nef. CEM HA-HLA-A2 and CEM HA-A2/CD4 cells were transduced as in part
A. Metabolic labeling with continuous surface biotinylation was performed in the presence of a cell-impermeable biotinylation reagent [NHS-biotin,
(Pierce)] to label cell surface proteins. The cells were lysed and immunoprecipitated first with an antibody against HLA-A2 or CD4 (part D) or anti-HA
(part E), then 2/3 was re-precipitated with avidin beads to selectively precipitate the HLA-A2 on the cell surface. Normalized surface MHC-I was
calculated as follows: ((surface MHC-I /total MHC-I62)6100). Quantitation for parts D and E represents the mean6standard deviation for four and
three independent experiments respectively. For part D, quantitation is derived from data for the lower of the two Nef levels shown.
doi:10.1371/journal.ppat.1000131.g001
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structural integrity of the Golgi
Because b-COP is known to be important for intra-Golgi and
ER-to-Golgi trafficking, we asked whether the Golgi structure or
MHC-I trafficking were drastically affected by reduced b-COP
expression. We found that there was only a small reduction in the
normal transport of MHC-I to the cell surface (35% reduction,
Figure 3D). In addition, cells lacking b–COP generally maintained
overall Golgi structure as assessed by the intracellular localization
of giantin, a transmembrane protein normally residing in the cis
and medial Golgi [51] (Figure 3E). In contrast, brefeldin A, an
inhibitor of an ARF1 GEF necessary for b-COP activity
obliterated the normal Golgi staining (Figure 3E, panel 9). The
relatively mild phenotype of this knock-down compared to the
drastic effects of brefeldin A, suggests that brefeldin A has effects
other than just disrupting COP 1 coats by blocking ARF1 activity.
Having established that knocking down b-COP allowed
relatively normal forward trafficking of HLA-A2, we proceeded
to assess the effect of knocking down b-COP or AP-1 in Nef-
expressing cells. Consistent with previous publications [25], we
found that knocking down the ubiquitously expressed form of AP-
1 (AP-1A [52]) largely reversed the effect of Nef on HLA-A2
(p,10
24), but had a smaller and less significant effect (p,0.02) on
CD4 surface expression (Figure 4A and 4B). Surprisingly, we also
observed that knocking down b-COP expression inhibited MHC-I
downmodulation by Nef and had a small but statistically
significant effect on CD4 downmodulation (p,10
23; Figure 4A
and 4B). The small effect of b-COP on CD4 surface expression
indicated that b-COP was not necessary for CD4 internalization
and downmodulation from the cell surface. However, further
studies were needed to determine whether b-COP was required to
degrade the CD4 after it was internalized.
A role for b-COP in promoting degradation of Nef cellular
targets
Prior studies had determined that expression of b-COP was
necessary for acidification of CD4-containing vesicles and thus it
was hypothesized that b-COP was needed to target vesicles
containing internalized CD4 for lysosomal degradation. There-
fore, we asked whether the role of b-COP in MHC-I trafficking
was also to promote MHC-I degradation. To examine this, we
utilized an assay we had developed, which measures the loss of
mature, endo H–resistant HA-tagged HLA-A2 in Nef expressing
cells by western blot analysis. This assay system is based on
previous data demonstrating Nef-dependent degradation of the
mature form of MHC-I in a manner that is reversible by inhibitors
of lysosomal degradation [25]. As shown in Figure 4C, under
normal, steady state conditions, most of the HLA-A2 is resistant to
endo H digestion, indicating that it has matured through the Golgi
apparatus (Figure 4C, lane 2). However, when Nef was expressed,
we observed a dramatic reduction in total MHC-I and a decrease
in the ratio of endo H resistant to sensitive protein (Figure 4C
compare lanes 2 and 18, see also Figure S3). Consistent with a role
for AP-1, we observed that AP-1A shRNA largely reversed this
effect of Nef (Figure 4C, compare lanes 18 and 20. See also
Figure 4D for quantification). To detect degradation of molecules
containing a CD4 tail, we used HA-A2/CD4 (Figure 1) and found
that Nef expression accelerated the degradation of endo H
resistant forms of this molecule (Figure 4C, compare lanes 6 and
22). However, we found that there was no effect of reduced AP-1A
expression on Nef-dependent degradation of molecules containing
the CD4 tail (Figure 4C, compare lanes 22 and 24. See also
Figure 4D for quantification).
When b-COP expression was reduced, we observed a small
increase in the amount of immature, endo H–sensitive protein
(Figure 4C, compare lanes 10 and 12), consistent with the 35%
reduction in export of MHC-I to the cell surface shown in
Figure 3D. However, we also noted that reduction in b-COP
expression reduced the Nef-dependent degradation of the mature,
endo H resistant form of these molecules (Figure 4C, compare
lanes 26 and 28. See also Figure 4D for quantification) implicating
b-COP in this pathway. We were also able to confirm the model
that b-COP is involved in Nef-dependent CD4 degradation as
treating cells with b-COP shRNA reduced the degradation of the
A2/CD4 chimeric molecule (Figure 4C, compare lanes 30 and 32.
See also Figure 4D for quantification).
b-COP is required for targeting internalized CD4 for
degradation in Nef-expressing T cells
We next directly examined the effect of reducing b-COP
expression on Nef-dependent trafficking by confocal microscopy.
For these experiments, cells were infected with HIV or were
transduced with Nef-expressing adenoviral vectors and then the
fate of internalized CD4 was assessed by confocal microscopy.
Using this assay system, we observed fairly rapid internalization of
CD4 in Nef-expressing cells, followed by loss of CD4 staining by
30 minutes (Figure 5A, compare control cells in row 1 to Nef-
expressing cells in row 3). However, in T cells expressing b-COP
shRNA, there was a three-to-four fold increase in the number of
CD4-containing vesicles, consistent with a role for b-COP in
promoting maturation of these vesicles into degradative compart-
ments (Figure 5A, compare control treated Nef-expressing cells in
row 3 to shb-COP–expressing cells in row 4). Reduction of b-COP
expression yielded similar results whether Nef was introduced
using HIV infection or via adenoviral vectors (Figure 5B and 5C).
b-COP is required for targeting MHC-I to LAMP-1
+
compartments in Nef-expressing T cells
Confocal analysis of MHC-I intracellular localization revealed
that expression of b-COP shRNA in control cells increased the
intracellular accumulation of MHC-I, consistent with the slowing
of export we observed in cells deficient in b-COP (Figure 5D,
compare rows 1 and 2). Infection with Nef-expressing HIV
resulted in the loss of cell surface MHC-I and an increase in
intracellular MHC-I, some of which co-localized with LAMP-1
(Figure 5D, compare rows 1 and 3). Under these conditions,
Figure 2. MHC-I and CD4 co-localize in a subset of vesicles in Nef-expressing T cells. (A) Three-way co-localization of HLA-A2, CD4 and
Rab7. CEM HLA-A2 cells stably expressing YFP-Rab7 were transduced with adeno-Nef. HLA-A2 (red), CD4 (green), and YFP-Rab7 (blue) were
simultaneously detected using three-color confocal microscopy. The top row shows the x–y projection of the cell, while the bottom row displays the
x–z projection. Ten sequential optical sections were compiled to generate a projection of each cell about the x–z plane. Scale bar=5 microns. (B)
Immunogold labeling of HLA-A2 and CD4. Representative electron micrographs of CEM HA-HLA-A2 cells treated with control adeno (column 1) or
adeno-Nef (columns 2 and 3). Thawed cryosections of cells were labeled with anti-HA (HLA-A2) and anti-CD4 antibodies followed by 15 and 10 nm
protein A-gold respectively. (C) Immunogold labeling of HA-HLA-A2 and c-adaptin in Nef-expressing CEM T cells. Thawed cryosections of cells were
labeled with anti-HA (HLA-A2) and anti-c-adaptin antibodies followed by 15 and 10 nm protein A-gold, respectively.
doi:10.1371/journal.ppat.1000131.g002
Nef-Induced MHC-I and CD4 Degradation
PLoS Pathogens | www.plospathogens.org 5 August 2008 | Volume 4 | Issue 8 | e1000131reduction of b-COP expression reduced the degree of colocaliza-
tion with LAMP-1 (Figure 5D, compare rows 3 and 4).
To enhance our ability to observe trafficking of MHC-I into
LAMP-1
+ compartments, we treated the cells with bafilomycin,
which inhibits the vacuolar ATPase and thus acidification and
degradation within lysosomal compartments. As previously
reported [25], bafilomycin treatment enhanced our ability to
detect MHC-I in LAMP-1
+ compartments in Nef-expressing T
Figure 3. Knockdown of b-COP does not affect HLA-A2 transport to the cell surface or disrupt the Golgi apparatus. (A) Analysis of
protein expression in b-COP and m1 knockdown cells. CEM HA-HLA-A2 cells were transduced with a lentivirus expressing both GFP and a control
shRNA (shNC) or an shRNA targeting either b-COP (shb-COP) or m1 (shm1). At 72 hours later, they were transduced with adeno-Nef or control
adenovirus. Three days later they were harvested, and western blot analysis was used to assess protein levels of b-COP, m1 and Nef. (B,C)
Quantification of m1 and b-COP expression in shRNA treated cells. The amount of either m1 (B) or b-COP (C) was quantified using Adobe Photoshop
software. The average percent remaining6standard deviation for four experiments (B) and three experiments (C) is shown. To adjust for protein
loading in part B, the nonspecific background band directly below m1 (shown in part A) was used to normalize protein loading. (D) Knockdown of b-
COP does not affect HLA-A2 transport to the cell surface. CEM HA-HLA-A2 cells were transduced with lentivirus expressing either shNC or shb-COP as
in part A. Cell surface transport was assessed using a metabolic labeling assay with biotinylation as described in Figure 1D. (E) Knockdown of b-COP
does not disrupt the Golgi apparatus. CEM HA-HLA-A2 cells were transduced with lentivirus expressing the indicated shRNA and GFP as in part A and
treated with brefeldin A (BFA) at 50 mM or DMSO for 30 minutes. The integrity of the Golgi apparatus was assessed by immunofluorescence staining
for giantin and analyzed by confocal microscopy. Images were taken using a Zeiss confocal microscope and analyzed with LSM Image Browser and
Adobe Photoshop software. Single Z-sections are shown. The results shown for parts D and E are representative of three independent experiments.
doi:10.1371/journal.ppat.1000131.g003
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shRNA decreased LAMP-1 colocalization with MHC-I, consistent
with a role for b-COP in targeting MHC-I for degradation in
lysosomal compartments in Nef expressing T cells (Figure 5D,
compare rows 7 and 8). Similar results were observed whether Nef
was introduced using HIV or adenoviral vectors (Figure 5E and
5F).
We also examined co-localization of HLA-A2 and CD4 in cells
that expressed b-COP shRNA. We observed that reduction of b-
COP expression resulted in increased staining of both proteins,
and did not disrupt their co-localization (Figure S4). Thus, b-COP
was not necessary for targeting these proteins into a common
endosomal pathway, but rather was needed for their subsequent
targeting into a degradative pathway.
The cytoplasmic tail of MHC-I is necessary for AP-1
binding in Nef-expressing T cells
To further explore the molecular mechanism for the similarities
and differences in MHC-I and CD4 trafficking in Nef-expressing
T cells, we asked whether these molecules differed as to how well
they bound Nef or cellular factors. As expected, we found that
HIV Nef bound to both the HLA-A2 and the CD4 tail (Figure 6A,
right panel). However, AP-1 only co-precipitated with molecules
containing the HLA-A2 cytoplasmic tail (Figure 6A, right panel).
The chimeric molecule with the CD4 cytoplasmic tail did not bind
AP-1 in Nef-expressing T cells (Figure 6A, right panel). In these
experiments, we noted that the expression level of A2/CD4 was
lower than for wild type HLA-A2, which could explain this
difference. Therefore, we confirmed these data using a fusion
Figure 4. Nef requires b-COP to reduce HLA-A2 cell surface expression and accelerate HLA-A2 degradation. (A) b-COP and m1 are
required for Nef to reduce cell surface expression of HLA-A2. CEM HA-HLA-A2 cells were transduced with a lentivirus expressing GFP and a control
(shNC), b-COP (shb-COP) or m1 (shm1) shRNAs and with control adenovirus (nef
2) or adeno-Nef (nef
+). Cell surface expression of HLA-A2 or CD4 in the
GFP-positive cells was assessed by flow cytometry. The gray shaded histogram represents control adenovirus (nef
2) treated cells and the solid black
line represents adeno-Nef (nef
+) treated cells. (B) Quantitation of HLA-A2 and CD4 downmodulation in Nef expressing cells transduced with shRNA.
The median fold downmodulation (median fluorescence of control/median fluorescence of Nef-expressing cells)6standard deviation derived from
five (HLA-A2) and four (CD4) independent experiments. A p value was calculated using a two tailed t-test and significant differences were indicated
with asterisks (*p,0.02, ***p,10
23, ****p,10
24). (C) Knockdown of b-COP stabilizes intracellular levels of HLA-A2 and A2/CD4 in Nef expressing
cells. CEM HA-HLA-A2 and CEM HA-A2/CD4 were treated as in part A. Lysates from these cells were generated and treated with endoglycosidase H
(endo H). Protein levels of HLA-A2 and A2/CD4 were assessed by western blot using an anti-HA antibody. Endo H–resistant bands are marked with an
R and endo H–sensitive bands are marked with an S. The results shown are representative of three independent experiments for HLA-A2 and two
independent experiments for A2/CD4. (D) Quantification of endo H–resistant protein. Adobe Photoshop software was used to quantify each band for
the Nef-expressing samples. The percentage of endo H–resistant protein in each condition was calculated as follows: [resistant band/(resistant
band+sensitive band)]6100. The fold stabilization was then calculated as: (% endo H–resistant in experimental sample)/[% endo H–resistant in
control (shNC)]. The data shown is the mean of two experiments6standard deviation.
doi:10.1371/journal.ppat.1000131.g004
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full length HIV-Nef protein. In previously published experiments
it was shown that the HLA-A2/Nef fusion protein co-precipitated
AP-1 in a manner that depended on sequences both in Nef and in
the HLA-A2 cytoplasmic tail [25]. Here we show again that the
HLA-A2 cytoplasmic tail was necessary for this interaction and,
moreover, that the CD4 tail could not substitute for it (Figure 6B,
right panel).
Evidence that formation of a Nef–b-COP complex is an
essential step necessary for MHC-I degradation
The Nef-b-COP interaction is well-described in the literature
[46] and there is evidence that b-COP interacts with a diacidic
motif (E154/155) within the Nef C-terminal loop [18]. However, this
region of Nef has never been implicated in MHC-I trafficking. To
provide further evidence that b-COP is needed to promote MHC-
I degradation, we sought to identify a region of Nef that is needed
both for MHC-I degradation as well as b-COP binding. We
therefore examined a panel of mutations (M20A, V10ED17–26 and
E62–65Q) that are specifically defective at disrupting MHC-I
trafficking [14,15,26,53]. We also examined a Nef mutant, D123G,
that is defective at both CD4 and MHC-I downmodulation [21].
The relative activity of these Nef mutants in MHC-I and CD4
downmodulation is shown in Figure 7A and quantified in
Figure 7B.
We then examined the relative ability of each of these mutant
molecules to co-precipitate with b–COP. As shown in Figure 7C,
we found that the V10E D17–26-Nef, which is defective at MHC-I
downmodulation, was also defective at binding to b-COP
(compare lanes 3 and 5). Interestingly, this deletion mutant is also
defective at interacting with AP-1 [25]. However, the b-COP
binding site was separable from the AP-1 interaction site because
M20, which is located within the deleted region, is needed for AP-1
interaction [25,27]), but was not necessary for b-COP binding to
Nef (Figure 7C, compare lanes 3 and 4). Mutation of the Nef
dimerization motif [D123G, [21]], which disrupts a number of Nef
functions, including MHC-I and CD4 downmodulation, also
reduced binding to b-COP (Figure 7C, compare lanes 3 and 7).
Finally, mutation of the Nef acidic domain (E62–65Q), which
disrupts binding to MHC-I [26], AP-1 [27,28] and PACS-1 [54],
did not affect binding to b-COP (Figure 7, compare lanes 3 and 6).
As expected, we found that V10ED17–26 Nef, which was
defective at b-COP binding, was also defective at inducing the
degradation of the endo H resistant form of HLA-A2 (Figure 7D,
upper panel, compare lanes 3 and 4 with lanes 5 and 6). In
contrast, V10ED17–26 Nef was not defective at A2/CD4
degradation based on western blot analysis (Figure 7D, lower
panel, compare lanes 3 and 4 with lanes 5 and 6). These data
suggested that there may be another interaction domain that
recruits b-COP to the Nef-CD4 complex to promote CD4
degradation. This would be consistent with the faint band
observable in the V10ED17–26-Nef mutant immunoprecipitation
(Figure 7C, lane 5, longer exposure) and prior publications
demonstrating that mutation of E154/155 also affected b-COP
binding [47]. Thus, there may be two independent binding sites
for b-COP within Nef, each of which governs the degradation of a
different cellular factor.
To further define the b-COP binding site, and to determine
whether there were indeed two b-COP binding sites, we
Figure 6. Selective binding of AP-1 is dependent on the
cytoplasmic tail. (A) The HLA-A2 cytoplasmic tail is necessary for co-
precipitation of AP-1. Parental HLA-A2-negative CEM T cells (CEM) or
CEM T cell lines expressing HA-HLA-A2 or HA-A2/CD4 were transduced
with adeno-Nef or a control adenovirus. Lysates were immunoprecip-
itated with an antibody directed against HLA-A2 (BB7.2) and the
presence of Nef or AP-1 was detected by western blot analysis. Results
are representative of three independent experiments. (B) The cytoplas-
mic tail is necessary for the HLA-A2/Nef fusion protein to co-precipitate
AP-1 in Nef expressing T cells. CEM T cells were transduced with a
murine retroviral vector expressing no protein (vector), A2/Nef or A2/
CD4/Nef fusion proteins. These cells were immunoprecipitated with an
anti-HLA-A2 antibody (BB7.2) and western blot analysis was performed
to detect co-precipitation of AP-1. Spaces between lanes indicate where
intervening lanes were cropped out to remove irrelevant data. Results
are representative of two independent experiments.
doi:10.1371/journal.ppat.1000131.g006
Figure5.Nefrequiresb-COPtotargetHLA-A2andCD4fordegradation.(A)Knockdownofb-COPstabilizesCD4
+vesiclesinNefexpressingcells.
CEM HA-HLA-A2 cells transduced with a lentivirus expressing GFP and either control shRNA (shNC) or shRNA targeting b-COP (shb-COP) were transduced
with control adenovirus (nef
2) or adeno-Nef (nef
+). The cells were incubated with CD4 antibody on ice and then shifted to 37uC for internalization for the
indicated times. Images were taken with a Zeiss confocal microscope and processed using LSM Image Browser and Adobe Photoshop software. Single Z-
sections are shown. (B) Quantitation of CD4
+ vesicles is shown for 15 GFP
+, nef
+ cells treated with shNC and 17 GFP
+, nef
+ cells treated with shb-COP. The
mean6standard deviation is shown. (C) Quantitation is shown for 5 GFP
+, nef
+ cells treated with shNC and 5 GFP
+, nef
+ cells treated with shb–COP. The
mean6standard deviation is shown. (D) CEM HA-HLA-A2 cells were transduced with a lentivirus expressing either GFP and control (shNC) or b-COP (shb–
COP) shRNA, infected with HIV, treated with bafilomycin or DMSO and stained for HLA-A2 and LAMP-1 as previously described [25]. Images were taken
with a Zeiss confocal microscope and processed as in part A. Single Z-sections are shown. (E) Relative co-localization of HLA-A2 with LAMP-1 in 10 GFP
+,
adeno-Nef-expressing T cells treated with shNC and 15 GFP
+, adeno-Nef-expressing T cells treated with shb-COP. (F) Relative co-localization of HLA-A2
withLAMP-1in 6 GFP
+,H I V - nef
+infectedT cellstreatedwithshNCand,6 GFP
+,H I V - nef
+–infected Tcells treatedwithshb-COP. Quantitationofmicroscopy
datawas performed independently by two blinded investigators who scored maximal observable co-localization among all cells atan arbitrary value of5 .
Each cell was then scored relative to that. The mean6standard deviation is shown.
doi:10.1371/journal.ppat.1000131.g005
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residues (R17ER19MR21R22) within the Nef deletion D17–26)
because previous studies had indicated that arginine rich regions
could form b-COP-binding sites [55]. Flow cytometric analysis of
MHC-I levels on cells expressing these mutants revealed that the
R17/19 pair was necessary for maximal MHC-I downmodulation
(Figure 8A and 8B). In contrast, mutation of R21/22 did not
significantly affect MHC-I downmodulation (unpublished data).
An assessment of Nef-induced degradation by pulse chase analysis
of HA-HLA-A2, revealed that mutating this motif also inhibited
Nef-dependent degradation (Figure 8C, compare lanes 5 and 7,
quantified in Figure 8D). Additionally, mutation of R17/19
reduced, but did not eliminate binding of b-COP to Nef in a
manner similar to the effect of the D17–26 Nef mutation
(Figure 8E, compare lanes 3 and 4).
We next examined the diacidic motif (E154/155) previously
implicated in b-COP binding. As shown in Figure 8A and 8B,
mutation of this motif did not disrupt MHC-I downmodulation, in
fact downmodulation was somewhat enhanced. Additionally, we
found that mutation of this motif did not reduce MHC-I
degradation (Figure 8C, compare lanes 5 and 11, see also
quantification in 8D). However, in agreement with prior results,
we observed a partial defect in b-COP binding with this mutant
(Figure 8E, compare lanes 3 and 6, [18,47]. However, this defect
was less reproducible (observed in two out of four experiments)
than that observed with disruption of R17/19 (consistently observed
in five out of five experiments), suggesting that binding to R17/19
can mask the defect observed with mutation of E154/155 under
certain conditions. To provide additional data supporting the
possibility that both sites contributed to b-COP binding, we
constructed a double mutant, R17/19 A and E154/155A (R/E). As
shown in Figure 8E, lane 5, binding of R/E to b-COP was further
reduced relative to binding of Nef proteins containing single
mutations in each motif, strongly implicating both motifs in b-
COP binding. The phenotype of the double mutant was highly
reproducible in 5 out of 5 experiments.
Interestingly, the R/E double mutant was not more defective
than R17/19A at downmodulating MHC-I (Figures 8A and 8B) or
at promoting MHC-I degradation (Figure 8C, compare lanes 7
and 9, quantified in 8D), indicating that Nef did not utilize the
E154/155 binding site to recruit b-COP for MHC-I degradation.
Conversely, we confirmed prior reports that the E154/155A mutant
was defective at CD4 degradation (Figure 9A, compare lanes 3
and 6) and determined moreover that there was no significant
effect of mutating R17/19 on CD4 degradation, either alone or in
combination with E154/155A (Figure 9A, compare lanes 3 and 4). It
is also worth noting that, in contrast to what was observed with
HLA-A2, we did not observe a clear correlation between the
relative CD4 surface expression and the relative level of total
cellular CD4 (compare Figure 8B and 9B), indicating that there
was a complex relationship between total cellular CD4 and the
fraction expressed on the cell surface.
Because the R17/19 motif is directly adjacent to M20, which is
necessary for AP-1 recruitment [25,27], we also examined whether
these mutations, which affect b-COP binding, also disrupted AP-1
co-precipitation. To accomplish this, we used our standard AP-1
recruitment assay in which proteins co-precipitating with MHC-I
HLA-A2 were detected by western blot analysis. As shown in
Figure S5, mutation of R17,19 (and E154/155) decreased AP-1
binding only slightly. Thus, the defects in MHC-I downmodula-
tion and degradation noted with mutation of R17,19 resulted
primarily from defects in b-COP binding.
Discussion
Expression of HIV Nef in infected cells protects them from lysis
by CTLs and this activity of Nef is due to downmodulation of
MHC-I surface expression. The Nef protein also prevents
superinfection and promotes viral spread by removing the viral
receptor, CD4 from the cell surface (for review see [56]). We
provide evidence that sequences in the cytoplasmic tail of these
molecules are important for determining whether Nef disrupts their
trafficking from the cell surface or at the TGN. These data, that
swapping cytoplasmic domains switches the initial pathways taken
by HLA-A2 and CD4 in the presence of Nef, may seem somewhat
obvious. Nef is always the same and thus one might conclude that
this information has to be contained in the modulated protein.
However, it was also possible that the ectodomain affected Nef
responsiveness by binding to other transmembrane proteins or by
altering intracellular trafficking. This was certainly a possibility for
MHC-I for which it is clear that the efficiency of peptide loading
can affect trafficking and we have found that trafficking rates affect
responsiveness to Nef and AP-1 binding [23].
Prior studies have demonstrated that Nef initially binds to hypo-
phosphorylated forms of the MHC-I cytoplasmic tail early in the
secretory compartment [23], but binding does not affect normal
transit through the Golgi apparatus and into the TGN [25]. The
Nef-MHC-I complex then recruits the AP-1 heterotetrameric
clathrin adaptor protein using a binding site that is created when
Nef binds the MHC-I cytoplasmic tail. This binding site requires a
methionine from the N-terminala helixofNefand atyrosineresidue
in the MHC-I cytoplasmic tail [25]. Additionally, there is evidence
that this complex is stabilized by the acidic and polyproline domains
of Nef [27,28]. Formation of this complex results in the re-direction
ofMHC-I trafficking insuch a way that itistargeted tolysosomes for
degradation [25]. However, cellular proteins that normally bind AP-
1 are not degraded, but rather recycled to the TGN (Figure 9C).
Here we present new evidence that Nef utilizes b-COP to promote
trafficking to degradative compartments (Figure 9C). Knocking
down expression of b-COP inhibited the degradation of MHC-I and
Figure 7. Co-precipitation of Nef and b-COP depends on domains of Nef that are also needed for MHC-I downmodulation. (A) Flow
cytometric analysis of Nef mutants defective at MHC-I downmodulation. CEM T cells treated with control adenovirus (nef
2), adeno-Nef (nef
+) or the
indicated mutant were stained either with an anti-HLA-A2 antibody (BB7.2) or an antibody directed at CD4. Cells were analyzed by flow cytometry as
described in Materials and Methods. (B) Quantitation of MHC-I and CD4 downmodulation by Nef and Nef mutants. Fold downmodulation was
determined by dividing the mean fluorescence intensity (MFI) of control virus treated cells by the MFI of Nef-expressing cells. The average value from
three (wild-type) or two (mutant Nef) experiments was plotted6the standard deviation. (C) Nef D123G and V10ED17–26 mutants are defective at b-
COP binding. CEM T cells were treated with control adenovirus (nef
2), adeno-Nef (nef
+), or the indicated mutant and immunoprecipitated with a
control antibody (BB7.2) or an antibody directed against b-COP (M3A5). The presence of Nef was detected by western blot analysis. Arrows indicate
the positions of wild type Nef and Nef V10ED17–26. Results are representative of at least two independent experiments. (D) V10ED17–26 Nef is
defective at MHC-I, but not CD4, degradation. CEM cells expressing HA-HLA-A2 and HA-A2/CD4 were transduced with adeno-viral vectors encoding
wild-type Nef (Nef
+), V10ED17–26 Nef, or a control adenoviral vector (Nef
2). Two days later, the media on half of the cells was replaced with media
containing 20 mM ammonium chloride to inhibit lysosomal degradation. The next day, the cells were harvested, lysed, and normalized. Each sample
was split equally and one set was treated with endo H. Protein levels of HA-HLA-A2 and HA-A2/CD4 were assessed by western blot analysis using an
anti-HA antibody. Endo H–resistant bands are marked with an R and endo H–sensitive bands are marked with an S.
doi:10.1371/journal.ppat.1000131.g007
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vesicles to LAMP-1
+ compartments. We also provide results here
that confirm b-COP is necessary for degradation of CD4 in
lysosomal compartments. Thus, we propose that AP-1 and AP-2
deliver MHC-I and CD4 respectively to endosomal compartments
where b-COP displaces AP-1 and AP-2 to target MHC-I and CD4
for lysosomal degradation (Figure 9C).
As described above, we found that knocking down b-COP with
shRNA resulted in stabilization of internalized CD4, however the
effect on CD4 surface expression was small, but still significant. In
contrast, there was a greater effect of b-COP knockdown on HLA-
A2 surface expression. This might suggest that the role of b-COP
in the modulation of these targets was different, rather than the
same. However, this apparent paradox can be explained by our
Figure 8. Two Nef domains recruit b-COP, but only one is used for the degradation of HLA-A2. (A) Flow cytometric analysis of HLA-A2
and CD4 expression in cells expressing Nef mutants. CEM T cells stably expressing HLA-A2 were spin-transduced with murine retroviral supernatants
that express the indicated Nef construct and a GFP cassette from an internal ribosomal entry site. The cells were gated for GFP expression and results
of HLA-A2 (top panel) or endogenous CD4 (bottom panel) staining are shown. R/E stands for R17,19A/E154,155A double mutant. Open light gray curve,
parental cell line; shaded dark gray curve, empty vector; black shaded curve, wild type Nef; and open dark gray curve, Nef mutant. (B) Quantification
of down-modulation. The mean6SD for greater than or equal to six experiments (actual number varies depending on the mutant) is shown. (C,D) R17/
19 is needed for optimal HLA-A2 degradation, whereas the E154/155 is dispensable. CEM T cells expressing HLA-A2 and Nef were generated as
described in part A. The cells were pulse labeled with
35S-labeled amino acids, chased for 0 or 12 hours in complete medium and lysed. HLA-A2 was
immunoprecipitated with the anti-HLA-A2 antibody BB7.2, separated by SDS-PAGE and quantified using a phosphorimager. ‘‘Ig Control’’ indicates
results from HLA-A2-negative parental CEM cells immunoprecipitated with BB7.2 antibody. (D) Quantification of degradation. Nef activity was
calculated as follows: (the fraction of HLA-A2 remaining in control cells /the fraction of HLA-A2 remaining in Nef expressing cells). The value obtained
for each mutant was divided by that for wild type Nef and multiplied by 100 to calculate % wild type activity. The mean6SD for two experiments is
shown. (E) R17/19 and E154/155 are required for the b-COP/Nef interaction. CEM T cells expressing HA-A2 were transduced with a retroviral vector
expressing either wild-type Nef or the indicated Nef mutant. The cells were immunoprecipitated with an anti–b-COP antibody and the presence of
Nef was assessed by western blot as described in Materials and Methods. The Ig control is HLA-A2–negative parental CEM cells expressing wild-type
Nef immunoprecipitated with a control antibody (BB7.2) and the vector only control is CEM cells expressing HLA-A2 transduced with the empty
retroviral vector.
doi:10.1371/journal.ppat.1000131.g008
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b-COP knockdown can be explained by differences in the
intracellular pathways of these proteins before they interact with
b-COP. MHC-I is engaged in an AP-1-dependent endosome-to-
TGN loop, and MHC-I could ‘‘leak’’ out to the cell surface from
the TGN in the absence of b-COP, whereas CD4 may be unable
to return to the cell surface from its endosomal compartment.
Consistent with this, we also noted a lack of correlation between
degradation and surface expression of CD4 (but not MHC-I) when
Nef mutants that were defective in b-COP binding were
examined. These data indicate that there is a complex relationship
between total cellular CD4 and the fraction that is present on the
cell surface and thus intracellular pools need to be directly
examined to assess degradation rather than relying on surface
expression as an indicator of the efficiency of this process.
It is also noteworthy that shRNA knockdown of b-COP did not
fully reverse Nef-dependent MHC-I and CD4 degradation. This
may have resulted from incomplete knockdown of b-COP.
However, we also observed a similar phenotype with Nef mutants
defective at b-COP binding. Failure to fully reverse degradation
may be secondary to a default degradative pathway that exists for
all proteins delivered to endosomal pathways. Alternatively, there
may be other ways Nef targets these proteins to lysosomes, which
have yet to be identified.
Our studies indicate that there are at least three domains
needed for Nef to interact efficiently with b-COP. One of these
domains (D123), is required for dimerization of Nef and is needed
to affect a variety of Nef functions [21]. Another region lies within
the N-terminal a helical domain of Nef that is specifically required
for disruption of MHC-I trafficking and for interactions with AP- 1
[25]. This binding site for b-COP is distinct from that used by AP-
1, because recruitment of b-COP does not require Nef’s acidic
domain or Nef M20, whereas AP-1 does [25,27]. The fact that
these Nef mutants bind b-COP, but are still defective at MHC-
downmodulation [53] makes sense, because these mutants are also
unable to bind the MHC-I cytoplasmic tail [26].
Additional mutants, which focused on the highly conserved
stretch of arginines in the N-terminal alpha helical domain of Nef
(R17XRMRR22), revealed that the regions involved in AP-1 and b-
COP binding were very closely apposed. However, we determined
that mutation of R17/19 affected primarily b-COP binding, with
only a minimal effect on AP-1 interaction. Thus, these two Nef-
interacting proteins have distinct and separable amino acid
requirements for binding.
The identification of a b-COP binding domain within a region
of Nef that is also required for Nef to accelerate MHC-I
degradation confirms the requirement for b-COP in this pathway.
In addition, the residual binding of b-COP to these Nef mutants
provided suggestive data that another binding site for b-COP
existed. Indeed, we were able to confirm prior evidence that a
diacidic motif within the C-terminal loop of Nef also promoted an
interaction with b-COP and that mutation of this motif reduced
CD4 degradation [47]. Finally, we demonstrated that mutation of
both the RXR and the diacidic motifs resulted in the greatest
defect in b-COP binding. The double mutant did not however
result in a greater defect in either MHC-I or CD4 degradation,
indicating the role of each motif is distinct and not additive. The
discovery of two distinct b-COP binding motifs helps explain why
some groups could not confirm the role of the diacidic motif in b-
COP binding [48] as both motifs need to be mutated to reliably
eliminate an interaction between b-COP and Nef.
There is precedent for such redundancy. For example, there are
two AP-1 binding sites within Nef; a dileucine motif within the C-
terminal flexible loop [16,31,32,33] as well as a second site that
forms upon binding of Nef to the MHC-I cytoplasmic tail. Despite
the presence of two AP-1 signals, only one is active in the context
of the natural Nef-MHC-I complex [25,27]. The dileucine motif
in the C-terminal flexible loop can become activated to affect
MHC-I transport, but only when Nef is artificially fused to the
MHC-I cytoplasmic tail [27]. This result indicates there is no
inherent inability of this signal to affect MHC-I traffic but rather
that something else, such as the structure of the natural complex,
causes the dileucine motif to be inactive [27]. The dileucine motif
Figure 9. Nef uses the E154/155 to promote maximal CD4
degradation. (A) Cells expressing HA-HLA-A2/CD4 were treated as in
Figure 8A, lysed and treated with endo H as indicated. The samples
were separated by SDS-PAGE and western blotted for the HA tag on
HA-A2/CD4. (B) Quantification of degradation. Western blots were
quantified using Adobe Photoshop software. Nef activity was calculated
as follows (fraction of total protein that was endo H–resistant for wild
type Nef/fraction endo H–resistant for each mutant)6100. The
mean6SD for four experiments is shown. (C) Model for the mechanism
by which Nef affects CD4 and MHC-I trafficking. HIV Nef binds the CD4
cytoplasmic tail at the cell surface, and recruits AP-2 and/or the
vacuolar-ATPase to facilitate internalization. CD4 is internalized and is
transported to an endosomal compartment associated with Rab7 and
b-COP. In contrast, Nef binds the MHC-I cytoplasmic tail early in the
secretory pathway, AP-1 is recruited and facilitates transport to an
intermediate endosomal compartment marked with Rab7. If AP-1 falls
off the Nef-MHC-I complex after arrival in the endosome, Nef binds b-
COP and targets MHC-I (and CD4) to lysosomes for degradation. If AP-1
remains bound, it promotes recycling of the Nef-MHC-I complex to the
TGN. LY=lysosome, LE/MVB=late endosome/multi-vesicular body.
doi:10.1371/journal.ppat.1000131.g009
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that binds b-COP to promote CD4 degradation. The fact that
both of these motifs are inactive when Nef is bound to MHC-I,
suggests that much of the C-terminal flexible loop region of Nef is
inaccessible under these conditions. Thus, Nef behaves as though
it assumes different structural forms in different contexts to
differentially expose distinct trafficking signals.
We also present evidence that knock down of b-COP yielded a
distinct phenotype from BFA treatment. As described above, BFA
is a chemical inhibitor of ARF1, that is known to trigger the
reversible collapse of the cis-medial Golgi compartments to the ER
[57–59] by inhibiting an ARF-specific guanine nucleotide-
exchange protein (ARF-GEF) [60,61]. Because ARF1 activity is
necessary for recruitment of b-COP to membranes [62], it was
possible that the dramatic effects of BFA resulted from the inability
for b-COP to function normally. However, our results demon-
strating that knockdown of b-COP had no effect on overall Golgi
structure indicate that the dramatic effects of BFA are not due
solely to disruption of b-COP function in the Golgi.
Given the important role of b-COP in the Golgi, it is surprising
that b-COP bound to Nef does not also affect transport of MHC-I
through the ER/Golgi. It is possible that our inability to detect an
effect of Nef on early transport of MHC-I [25] may be a result of
the cell type chosen for these studies. T cells, which are an
important natural target of HIV, normally traffic MHC-I through
the early secretory pathway slowly [23] and thus it might be
difficult to further reduce the trafficking speed through an
interaction with b-COP. Interestingly, another group has reported
a reduced ER-Golgi exit rate for MHC-I in Nef-expressing HeLa
cells [63], which normally transport MHC-I more rapidly than T
cells [23]. We have made similar observations in astrocytoma cells
expressing higher levels of Nef than typically needed to observe
MHC-I downmodulation (Roeth and Collins, unpublished
observations). Further studies will be needed to determine whether
this effect of Nef plays a role in more physiologically relevant cell
systems and whether this effect of Nef might be dependent on b-
COP expression.
ArecentreportindicatesthattheeffectofNefoninternalizationof
MHC-I, which is only minimally apparent in our system, occurs via
aPI3-kinasedependentpathway[64].Thispublicationreportedthat
CEM cells, which were used in our study, have less PTEN (a
phosphatase that inhibits PI3-kinase) than another T cell line used in
their study (H9). This deficiency might make it relatively more
difficult for us to detect an effect of chemical PI3-kinase inhibitors,
but would not affect our ability to detect a PI3-kinase-dependent
trafficking pathway. In fact, one would expect the opposite, that the
PI3-kinase-dependent pathway would be more active in our system.
However, we have found that Nef has a relatively small effect on
internalization of MHC-I, and mainly affects MHC-I protein export
and degradation. These data have been corroborated in HIV-
infected primary T cells [22,26], which were also found to much
lower levels of PTEN than H9 cells did [64].
From a teleological perspective, it makes sense that Nef would
have evolved to target early forms of MHC-I, which harbor
antigens derived from the newly synthesized viral proteins. Older
forms of MHC-I already on the cell surface would be bound to
normal cellular antigens and would in fact be protective as they
would inhibit killing by natural killer cells that are stimulated to
lyse cells with abnormally low MHC-I expression. On the other
hand, it makes sense that Nef, an early viral protein, would have
evolved to target surface CD4 to rapidly and efficiently remove
CD4 in order to prepare the cell for rapid release of viral particles
and to render the cell resistant to re-infection. Meanwhile, a late
protein, Vpu, is expressed in infected cells and specifically targets
the newly synthesized CD4 for degradation, preventing any
additional CD4 from reaching the cell surface [65].
In sum, we have found that the HIV Nef protein commandeers
the cellular trafficking machinery efficiently by utilizing their
natural activities for abnormal purposes. The fact that these
pathways may end in a final common step raises the important
possibility that inhibitors might be developed that could block
multiple Nef functions.
Materials and Methods
Cell lines
CEM T cells stably expressing HA-tagged HLA-A2 (CEM HA-
HLA-A2) have already been described [25]. Cell lines stably
expressing YFP-tagged Rab7 or HA-HLA-A2/CD4 were made by
transducing cells with murine retroviral constructs (MSCV YFP-
Rab7 or MSCV HA-A2/CD4) as previously described [22],
followed by culture in selective media.
DNA constructs
MSCV YFP-Rab7 was constructed by cloning a filled-in a Kpn
I-Xho I fragment from pEYFP-Rab7 [66] into MSCV puro [67].
MSCV HA-A2/CD4 was constructed using PCR mutagenesis.
The first round PCR produced two products: the first utilized 59
primer (primer 1) 59-CGGGATCCACCATGCGGGTCACGG-
CG-39 and 39 primer (primer 2) 59-CTCTGCTTGGCGCCT-
TCGGTGCCACATCACAGCAGCGACCAC-39 with MSCV
HA-HLA-A2 as the template [25]. The second utilized 59 primer
(primer 3) 59-GTGGTCGCTGCTGTGATGTGGCACCGAA-
GGCGCCAAGCAGAG-39 and 39 primer (primer 4) 59-CCTCG-
AGTCAAATGGGGCTACATGTCTTCTGAAATCGGTGA-
GGGCACTGG-39 using CD4 as the template. The second round
utilized primers 1 and 4 from the previous PCR reactions plus 1 ml
of each purified first round PCR reactions as template. The
resulting product was digested with BamHI and XhoI and ligated
into MSCV 2.2 [67] digested with BglII and XhoI.
MSCV A2/Nef has been described [26]. MSCV HA-A2/CD4/
Nef was constructed using a PCR mutagenesis approach. The first
round PCR produced two products: the first utilized 59 primer
(primer 1) 59-CGGGATCCACCATGCGGGTCACGGCG-39
and 39 primer (primer 2) 59-CCACTTGCCACCCATACTAG-
TAATGGGGCTACATGT-39 with MSCV HA-A2/CD4 as the
template. The second utilized 59 primer (primer 3) 59-ACATG-
TAGCCCCATTACTATGATGGGTGGCAAGTGG-39 and 39
primer (primer 4) 59- GCGAATTCTCAGCAGTTCTTGAAG-
TACTC-39 with NL4-3 Nef open reading frame as template. The
second round utilized primers 1 and 4 from the previous PCR
reactions plus 1 ml of each purified first round PCR reactions as
template. The resulting product was digested with BamHI and
EcoRI and ligated into MSCV IRES GFP [68] digested with BglII
and EcoRI.
Nef mutants were made by using the PCR mutagenesis
approach described previously (Wonderlich et al. 2008). The
mutagenesis primers were as follows: R17/19A5 9-TGGCCTAC-
TGTAGCGGAAGCAATGAGACGAGCT-39 and EE154–155AA
59-GTTGAGCCAGATAAGGTAGCAGCGGCCAATAAAG-
GAGAGA-39. Each primer, plus its reverse complement were
utilized together with additional 59 and 39 primers to generate the
mutated product. Wild type NL4-3 Nef [MSCV A2/Nef IRES GFP
(Roeth et al 2005)] was used as a template for the PCR reaction,
except for the double mutant, R17/19A/EE154–155AA, in which the
MSCV R17/19A Nef IRES GFP was used as the template. Each
mutated PCR product was digested and cloned into MSCV IRES
GFP [68] as described previously (Wonderlich et al. 2008).
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previously described [50]. Briefly, complementary primers were
annealed together and ligated into vector pRNAi [69] digested with
BglII and HindIII. The sequences of the primers were as follows (the
target sequence is underlined): shNC (an siRNA directed at GFP,
with several base changes [25])- sense 59-GATCCCCGCTCA-
CACTGAAGTTAATCTTCAAGAGAGATTAACTTCAGTG-
TGAGCTTTTTGGAAA-39,a n t i s e n s e5 9-AGCTTTTCCAAAA-
AGCTCACACTGAAGTTAATCTCTCTTGAAGATTAACT-
TCAGTGTGAGCGGG-39,sh b-COP-sense59-GATCCCCTGA-
GAAGGATGCAAGTTGCTTCAAGAGAGCAACTTGCATC-
CTTCTCATTTTTGGAAA-39,a n t i s e n s e5 9-AGCTTTTCCAA-
AAATGAGAAGGATGCAAGTTGCTCTCTTGAAGCAACT-
TGCATCCTTCTCAGGG-39;s h m1A- (a mixture of two lentivi-
ruses was used) (1) sense 59GATCCCCTGAGGTGTTCTTGGA-
CGTCTTCAAGAGAGACGTCCAAGAACACCTCATTTTT-
GGAAA-39,a n t i s e n s e5 9-AGCTTTTCCAAAAATGAGGTGTT-
CTTGGACGTCTCTCTTGAAGACGTCCAAGAACACCTC-
AGGG-39, (2) sense 59-G A T C C C C CGACAAGGTCCTCTTT-
GACTTCAAGAGAGTCAAAGAGGACCTTGTCGTTTTTG-
GAAA-39, and antisense 59- AGCTTTTCCAAAAACGACAA-
GGTCCTCTTTGACTCTCTTGAAGTCAAAGAGGACCTT-
GTCGGGG-39. The pRNAi constructs were digested with XbaI
and XhoI to remove the promoter and shRNA sequence. The
resulting fragment was ligated into FG12 [50], digested with XbaI
and XhoI.
Virus preparation and transductions
Adenovirus was prepared by the University of Michigan Gene
Vector Core facility. Adenoviral and HIV (HXB-EP [6])
transductions of T cells [25] or 373 mg astrocytoma cells [49]
have been described previously. Murine retroviral vector (MSCV)
expressing Nef was prepared as described previously (Roeth et al.
2005), except that in some cases the retroviral vector supernatants
were concentrated by spinning at 14000 RPM for four hours at
4uC. The viral pellet was then resuspended in media to yield a
twenty-fold concentrated stock. Lentiviruses expressing shRNA
were generated using an approach similar to that already
described [50]. Briefly, 293 cells were transfected with the FG12
constructs described above plus pRRE [70], pRSV-Rev [70] and
pHCMV-G [71] using Lipofectamine 2000 (Invitrogen). Super-
natants from the transfected cells were collected and used to
transduce CEM T cells using a spin-transduction protocol.
Flow cytometry and internalization assays
Intact cells were stained for flow cytometry analysis as
previously described [24]. Briefly, HLA-A2 was detected with
BB7.2 [72] that had been purified as previously described [22].
Endogenous CD4 was detected using RPA-T4 from Serotec. The
secondary antibody was goat anti-mouse-phycoerythrin (Bio-
Source, 1:250). For experiments using the GFP-expressing FG12
lentivirus for shRNA expression, the GFP-positive cells were gated
to identify the subset of transduced cells (generally .90% of cells).
Endocytosis assays were performed as previously described with
minor modification [22]. Briefly, cells were washed once with
Endocytosis Buffer [D-PBS, 10 mM HEPES, 10 mg/ml BSA
(NEB)], then stained with primary antibody (described above) for
20 minutes on ice. After washing, the cells were resuspended in
RPMI supplemented with 10% fetal bovine serum, 10 mM
HEPES buffer, 2 mM L-glutamine, penicillin and streptomycin
(R10) (pre-warmed to 37uC) and replicate aliquots were removed
and placed on ice for each time point. Cells were then washed and
stained with goat anti-mouse-phycoerythrin (BioSource, 1:250)
and the samples were analyzed using a FACScan flow cytometer
(Becton Dickinson). Flow cytometry data was processed using
FlowJo v4.4.3 software (Treestar Corp.). The mean fluorescence at
time zero was set to 100%, and this value was used to calculate the
relative surface staining at each subsequent time point.
Cell surface transport assay
CEM cells transduced with adenoviral vectors as previously
described [22] were first incubated in pre-label media [RPMI –
Cys –Met (Specialty Media, Inc.)+10% dialyzed FBS (Invitrogen)]
for 15 minutes at 37uC. Pulse labeling was performed in pre-label
media with 150–200 mCi/ml Pro-mix-L [
35S] (.1000 Ci/mmol;
Amersham Pharmacia) for 30 minutes at 37uC. The cells were
then chased in R10 media for 15 minutes at 37uC, followed by two
washes with D-PBS. To label the protein that reached the cell
surface, the cells were resuspended in D-PBS containing 0.5 mg/
ml EZ-Link sulfo-NHS-LC-Biotin (Pierce), and incubated at 37uC
for 1 hour. Surface biotinylation was quenched by washing the
cells in D-PBS+25 mM Lysine (Fisher).
For Figure 1D, immunoprecipitation of proteins from cell
lysates was performed as previously described [25], except that
one-third of the total lysate was used for the HLA-A2
immunoprecipitation while two-thirds of the material was used
to recover CD4. For immunoprecipitations of
35S labeled proteins,
5 mg of BB7.2 and 2.5 mg RPTA4 (BD Pharmingen) were used for
HLA-A2 and CD4 respectively. In Figure 1E and 3D, the total cell
lysate was immunoprecipitated with anti-HA ascites (HA.11,
Covance).
For Figures 1D, 1E and 3D, recovered proteins were released
from the beads by boiling in 100 ml of 10% SDS. One third was
analyzed directly by SDS-PAGE (Total). The remaining two thirds
was brought to a total volume of 1 ml in RIPA Buffer [25], and
40 ml of avidin-agarose (Calbiochem) was added to recover
biotinylated proteins. After 2 hours at 4uC, the beads were
washed three times with 1 ml RIPA buffer and proteins were
separated by SDS-PAGE (Surface).
Immunofluorescence microscopy
Adeno-transduced CEM cells were adhered to glass slides, fixed,
permeabilized, and stained for indirect immunofluorescence as
previously described [25]. Bafilomycin treatment was performed
as described previously [25]. The following antibodies were
utilized to localize proteins via microscopy: Figure 2, and Figures
S1 and S4; anti-CD4 (S3.5, Caltag Laboratories) and anti-HLA-
A2 (BB7.2); Figure 3; anti-giantin (Covance); Figure 5; anti-CD4
antibody (S3.5, Caltag Laboratories), anti-LAMP-1 (H4A3, BD
Pharmingen) and anti-HLA-A2 (BB7.2). Secondary antibodies
were obtained from Molecular Probes and were used at a dilution
of 1:250: Giantin, Alexa Fluor 546 goat anti-rabbit; CD4, Alexa
Fluor 546 goat anti-mouse IgG2a; LAMP-1, Alexa Fluor 546 goat
anti-mouse IgG1; BB7.2 (Figures 2, 5D and S4), Alexa Fluor 647
goat anti-mouse IgG2b; BB7.2 (Figure S1), Alexa Fluor 488 goat
anti-mouse IgG2b. See Table S2 for a summary of antibodies used
to gather data for Table S1.
For the microscopy based internalization assay in Figure 5A,
CEM T cells were allowed to adhere to glass slides, and placed on
ice. The cells were washed once with wash buffer (D-PBS, 10 mg/
ml BSA (NEB) and 2% goat serum), incubated with anti-CD4
antibody (S3.5, Caltag Laboratories, IF, 1:25) for 20 minutes,
washed once with wash buffer, incubated with Alexa fluor 546
goat anti-mouse IgG2a (Molecular Probes, 1:250) for 20 minutes
and washed once with wash buffer. The zero time point was fixed
with 2% paraformaldehyde, while the remaining time points
incubated at 37 ˚C for the indicated time. The cells were then fixed
with 2% paraformaldehyde. Images were collected using a Zeiss
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Photoshop software. Three-dimensional projections of cells were
generated from Z-stacks using Zeiss LSM Image Examiner
software. Otherwise, single Z sections through the center of the
cell were displayed.
Electron microscopy
Electron microscopy with CEM cells transduced with adenovi-
rus was performed by the Harvard Medical School (HMS)
Electron Microscopy Facility. Frozen samples were sectioned at
2120uC, the sections were transferred to formvar-carbon coated
copper grids and floated on PBS until the immunogold labeling
was carried out. The gold labeling was carried out at room
temperature on a piece of parafilm. All antibodies and protein A
gold were diluted in 1% BSA. The diluted antibody solution was
centrifuged 1 minute at 14,000 rpm prior to labeling to avoid
possible aggregates. Grids were floated on drops of 1% BSA for
10 minutes to block for unspecific labeling, transferred to 5 ml
drops of primary antibody and incubated for 30 minutes. The
grids were then washed in 4 ml drops of PBS for a total of
15 minutes, transferred to 5 ml drops of Protein-A gold for
20 minutes, washed in 4 ml drops of PBS for 15 minutes and 6 ml
drops of double distilled water. Contrasting/embedding of the
labeled grids was carried out on ice in 0.3% uranyl acetete in 2%
methyl cellulose for 10 minutes. Grids were picked up with metal
loops (diameter slightly larger than the grid) and the excess liquid
was removed by streaking on a filter paper (Whatman #1), leaving
a thin coat of methyl cellulose (bluish interference color when dry).
The grids were examined in a Tecnai G
2 Spirit BioTWIN
transmission electron microscope and images were recorded with
an AMT 2k CCD camera.
Western blot analyses and immunoprecipitations
For the western blot analysis in Figures 3A, 4C, 7D, 9A, S2, and
S3, cells were lysed in PBS 0.3% CHAPS, 0.1% SDS pH 8, 1 mM
PMSF, normalized for total protein and separated by SDS-PAGE.
Endo H (NEB) digestion was performed according to the
manufacturer’s protocol. Staining of the western blot was
performed using anti-Nef (AG11, [73]) and anti-b-COP (M3A5
[74]), which were purified as previously described [22]. Additional
antibodies used were HA (Covance) and m1 (RY/1 [75]). The
secondary antibody for anti-Nef, b-COP, and HA was HRP-rat
anti-mouse IgG1 (Zymed) and for anti-m1 was HRP-goat anti-
rabbit (Zymed).
For Figure 6B, the IP-western experiment was performed as
previously published [26]. Briefly, parental CEM T cells were
spin-transduced with murine retroviral supernatant expressing
either empty vector, A2/Nef or A2/CD4/Nef. At 72 hours post
transduction, the cells were incubated in 20 mM NH4Cl for
4 hours. The cells were then treated with DTBP (Pierce) for
40 minutes, quenched per the manufacturer’s protocol, and lysed
in PBS with 0.3% Chaps and 0.1% SDS. The lysate was pre-
cleared and immunoprecipitated with HLA-A2 with BB7.2
chemically crosslinked protein A/G beads (Calbiochem) [25].
The immunoprecipitates were washed in TBS with 0.3% CHAPS
and 0.1% SDS. A more stringent IP protocol was used in
Figures 6A, 7C, 8E, and S5. For these experiments, CEM cells
were transduced with control, wild type Nef, or mutant Nef
expressing adenovirus (Figure 6A and 7C) or concentrated MSCV
(Figures 8E and S5). At 48 hours post-transduction, the cells were
incubated in 20 mM NH4Cl for 16 hours. The cells were not
crosslinked and were lysed in digitonin lysis buffer (1% digitonin
(Wako), 100 mM NaCl, 50 mM Tris pH 7.0, 1 mM CaCl2, and
1 mM MgCl2). After pre-clear, the lysates were immunoprecipi-
tated with either BB7.2 (Figures 6A and S5) or M3A5 (Figures 7C
and 8E) crosslinked to beads. The immunoprecipitates were eluted
and analyzed by western blot as described previously [26].
Pulse-chase analysis of protein degradation
A total of 30 million CEM T cells transduced with wild type or
mutant Nef using concentrated MSCV as described above were
pulse labeled for 30 minutes with [
35S]-methionine and cysteine.
Half of the cells were collected as the zero time point and stored at
220 degrees. The remaining cells were then chased for 12 hours
in RPMI, collected and stored at 220 degrees. Lysates were
generated in lysis buffer (PBS 0.3% CHAPS, 0.1% SDS pH 8,
1 mM PMSF) and precleared over night. They were immuno-
precipitated for two hours with an anti-HLA-A2 antibody (BB7.2)
and washed once in radioimmunoprecipitation assay (RIPA) buffer
(50 mM Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% deoxycho-
late, 0.1% SDS). The immunoprecipitates were then eluted by
boiling in 10% SDS, reprecipitated with an antibody against HA
(HA.11, Covance), and washed two times in RIPA buffer. The
final immunoprecipitates were then separated by SDS-PAGE, the
gel was dried down and analyzed using a phosphorimager.
Supporting Information
Table S1 Analysis of CD4
+ structures in Nef-expressing T cells.
CEM HLA-A2 cells were transduced with adeno-Nef and
analyzed by three-color confocal microscopy as described in
Materials and Methods. Discrete CD4
+ structures were identified
and scored for co-localization with HLA-A2 or the indicated
organelle marker protein. Data from at least two independent
experiments were combined for each protein analyzed.
Found at: doi:10.1371/journal.ppat.1000131.s001 (0.02 MB
DOC)
Table S2 Combinations of antibodies used for immunofluores-
cence staining for experiments summarized in Table S1.
Found at: doi:10.1371/journal.ppat.1000131.s002 (0.04 MB
DOC)
Figure S1 Bafilomycin treatment increases MHC-I and CD4 co-
localization in Nef-expressing cells. CEM HA-HLA-A2 cells were
transduced with a control adenovirus (nef
2) or adeno-Nef (nef
+)a s
described in Materials and Methods. At 72 hours later, the cells
were treated with bafilomycin or solvent control (DMSO) and
stained with antibodies directed against HLA-A2 and CD4 as
described in Materials and Methods. Images were taken with a
Zeiss confocal microscope and processed with LSM Image
Browser and Adobe Photoshop software. Single Z-sections are
shown.
Found at: doi:10.1371/journal.ppat.1000131.s003 (1.44 MB TIF)
Figure S2 A second siRNA directed at b-COP disrupts Nef-
dependent MHC-I trafficking. (A) Western blot analysis of protein
expression in 373 mg astrocytoma cells transfected with the
indicated siRNA. Previously published protocols [25] were used to
transfect 373 mg astrocytoma cells with control siRNA (siGFP
[25]) an siRNA targeting b-COP (sib-COP, sense 59-GGAGAU-
GUAAAGUCAAAGA-39, antisense 59-UCUUUGACUUUA-
CAUCUCC-39, Ambion) or an siRNA targeting the AP-1 m
subunit (si m 1 [25]). The data is representative of three
experiments. (B) b-COP and m 1 are required for Nef to efficiently
reduce cell surface expression of HLA-A2. HLA-A2 cell surface
expression on astrocytoma cells from (A) was assessed by flow
cytometry as described in Materials and Methods. The fold
downmodulation of HLA-A2 (mean fluorescence intensity of
control/mean fluorescence intensity of Nef-expressing cells) for
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of HLA-A2 fold downmodulation in Nef expressing cells treated
with siRNA. The mean fold downmodulation6standard deviation
from three experiments is shown.
Found at: doi:10.1371/journal.ppat.1000131.s004 (0.24 MB TIF)
Figure S3 (A) Characterization of HA-HLA-A2 protein forms
using western blot analysis. CEM T cells expressing HA-HLA-A2
were lysed and treated with either Endo H or neuraminidase. The
samples were then analyzed via Western blot. (B) CEM T cells
expressing HA-HLA-A2 and Nef or a control adenoviral vector
were lysed, normalized for total protein, digested with endo H,
and probed for HA-HLA-A2 by Western blotting with an anti-HA
antibody.
Found at: doi:10.1371/journal.ppat.1000131.s005 (0.24 MB TIF)
Figure S4 Shb-COP does not disrupt co-localization of CD4
and HLA-A2, but does increase the amount of stainable protein
within the cell. HLA-A2 CEM cells were transduced with a
lentivirus expressing control (shNC) or b-COP (shb-COP) shRNA.
After 3 days, the cells were transduced with adeno-Nef. After three
additional days, the cells were stained with antibodies directed
against HLA-A2 and CD4 as in Figure S1. Images were taken with
an Olympus FV-500 confocal microscope and processed with
Adobe Photoshop software. Single Z-sections are shown.
Found at: doi:10.1371/journal.ppat.1000131.s006 (0.54 MB TIF)
Figure S5 Mutation of R17/19 and E154/155 only slightly
diminishes the amount of Nef and AP-1 coprecipitating with HLA-
A2. CEM cells expressing HA-HLA-A2 were transduced with a
retroviral vector expressing either wild type Nef or the indicated
Nef mutant. The cells were immunoprecipitated with an anti-
HLA-A2 antibody (BB7.2), and the presence of Nef was assessed
by Western blot as described in Materials and Methods. ‘‘Control’’
indicates lysates from parental CEM T cells that lack HLA-A2, but
that express wild-type Nef. ‘‘Vector only’’ indicates CEM T cells
expressing HA-A2 transduced with empty retroviral vector.
Found at: doi:10.1371/journal.ppat.1000131.s007 (0.29 MB TIF)
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